|
|
OVA-csNLCs |
|
Vaxjo ID |
249 |
|
Vaccine Adjuvant Name |
OVA-csNLCs |
|
Alternative Names |
Ovalbumin-loaded chitosan-modified nanostructured lipid carriers |
|
Adjuvant VO ID |
VO_0005736
|
|
Description |
A vaccine delivery system combining ovalbumin (OVA) as the model antigen with chitosan-coated nanostructured lipid carriers (csNLCs) to improve antigen uptake and immune activation . |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
nanoparticles to develop a functionalized and cationic nanoparticle delivery system (OVA-csNLCs) |
|
Structure |
Nanoscale lipid core with chitosan shell; encapsulates OVA protein for controlled release and enhanced uptake . |
|
Preparation |
Formulated via high-shear homogenization and ultrasonication, followed by chitosan coating for enhanced mucoadhesion and stability . |
|
Function |
model antigen ovalbumin (OVA) was encapsulated into squalene-based nanostructured lipid carriers (NLCs), and the chitosan, a cationic polysaccharide, was used for modifying nanoparticles to develop a functionalized and cationic nanoparticle delivery system (OVA-csNLCs). |
|
Safety |
Safe in mice |
| References |
Gao et al., 2021: Gao X, Gong J, Cai Y, Wang J, Wen J, Peng L, Ji H, Jiang S, Guo D. Chitosan modified squalene nanostructured lipid carriers as a promising adjuvant for freeze-dried ovalbumin vaccine. International journal of biological macromolecules. 2021; 188; 855-862. [PubMed: 34411614].
|
|
